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ttp://dx.doi.org/10.1016/j.ajpath.2013.05.011Vascular endothelial growth factor (VEGF) A is implicated in aberrant angiogenesis and intravitreous
neovascularization (IVNV) in retinopathy of prematurity (ROP). However, VEGFA also regulates retinal
vascular development and functions as a retinal neural survival factor. By using a relevant ROP model,
the 50/10 oxygen-induced retinopathy (OIR) model, we previously found that broad inhibition of
VEGFA bioactivity using a neutralizing antibody to rat VEGF signiﬁcantly reduced IVNV area compared
with control IgG but also signiﬁcantly reduced body weight gain in the pups, suggesting an adverse
effect. Therefore, we propose that knockdown of up-regulated VEGFA in cells that overexpress it under
pathological conditions would reduce IVNV without affecting physiological retinal vascular devel-
opment or overall pup growth. Herein, we determined ﬁrst that the VEGFA mRNA signal was located
within the inner nuclear layer corresponding to CRALBP-labeled Müller cells of pups in the 50/10 OIR
model. We then developed a lentiviral-delivered miR-30eembedded shRNA against VEGFA that tar-
geted Müller cells. Reduction of VEGFA by lentivector VEGFA-shRNAetargeting Müller cells efﬁciently
reduced 50/10 OIR up-regulated VEGFA and IVNV in the model, without adversely affecting physi-
ological retinal vascular development or pup weight gain. Knockdown of VEGFA in rat Müller cells by
lentivector VEGFA-shRNA signiﬁcantly reduced VEGFR2 phosphorylation in retinal vascular endothelial
cells. Our results suggest that targeted knockdown of overexpressed VEGFA in Müller cells safely
reduces IVNV in a relevant ROP model. (Am J Pathol 2013, 183: 964e974; http://dx.doi.org/
10.1016/j.ajpath.2013.05.011)Supported by NIH grants R01 R01EY015130 and R01EY017011
(M.E.H.) and Research to Prevent Blindness, Inc. (New York, NY), unre-
stricted grant (Department of Ophthalmology and Visual Sciences,
University of Utah).
H.W. and G.W.S. contributed equally to this work.Retinopathy of prematurity (ROP) remains a leading cause
of childhood blindness and is increasing in frequency in
developing countries. The hypothetical proposed patho-
physiological characteristics of ROP have been recently
reﬁned to be that stresses in prematurity cause delayed
physiological retinal vascular development and potentially
some high oxygen-induced capillary constriction that results
in avascular retina.1e4 Once supplemental oxygen is
removed from the preterm infant, the retina becomes
hypoxic, and hypoxia stimulates the release of angiogenic
factors with growth of new blood vessels into the vitreous as
intravitreous neovascularization (IVNV). Many angiogenic
factors can result in pathological IVNV in animal models,stigative Pathology.
.such as insulin-like growth factor-1,5,6 hepatocyte growth
factor,7 erythropoietin,8e10 platelet-derived growth factor,11
and angiopoietins,12,13 but vascular endothelial cell growth
factor A (VEGFA) has become one of the most studied
factors leading to IVNV. VEGFA mRNA was found in the
retina of a preterm infant eye with severe ROP,14 and
VEGFA protein was increased in vitreous from preterm
Müller CelleDerived VEGFA Regulates IVNVinfants who underwent surgery for stage 4 ROP compared
with controls.15 VEGFA inhibitors reduce pathological
angiogenesis in adult retinal diseases, including diabetic
retinopathy16,17 and age-related macular degeneration.18e20
Therefore, there is reason to consider VEGFA in the path-
ological characteristics of human ROP. However, in the
preterm infant retina, VEGFA is also important in the
development of retinal blood vessels21e23 and other
organs.24,25 After a recent clinical trial testing intravitreal
delivery of a broad anti-VEGFA antibody in infants with
severe ROP, there have been reports of persistent avascular
retina and reactivation of IVNV with subsequent total retinal
detachment, even 1 year after treatment.26 In addition, by
using a relevant ROP model, we found that inhibition of
VEGFA bioactivity using a neutralizing antibody to rat
VEGF signiﬁcantly reduced IVNV area without adversely
affecting physiological retinal vascular development 6 days
after antibody injection, but signiﬁcantly reduced body
weight gain in the pups, suggesting an adverse effect.27
Therefore, safer ways to inhibit pathological IVNV while
preserving physiological retinal vascularization are needed.
One way to target pathological IVNV is to determine the
cells within the retina that overproduce VEGFA during
pathological stress. In preterm infant eyes, it is not possible
to safely localize where VEGFA is produced. Therefore, we
used a relevant model of ROP today, the rat 50/10 oxygen-
induced retinopathy (OIR) model, to localize the VEGFA
signal within the retina and determine its role in pathological
IVNV in ROP. This model causes features of severe ROP
and produces extrauterine growth restriction, a risk for ROP
in human preterm infants.28 The oxygen exposure recreates
arterial oxygen ﬂuctuations similar to those experienced by
infants with severe ROP.29 Previously, we found that
VEGFA and VEGFR2 were both increased as early as at
postnatal day 8 (p8) in whole retinas from eyes of pups in
the 50/10 OIR model compared with room aireraised
counterparts.30
In the retina, several cells have been shown to produce
VEGFA to support retinal development and physiological
functioning. These include ganglion cells,31 astrocytes,32
Müller cells, and retinal pigment epithelium.33 In patho-
logical IVNV, the VEGFA signal has been localized to
many of the same cells: Müller cells,34,35 astrocytes,36
and, possibly, ganglion cells. However, there has been
disagreement as to the cell type that overproduced
VEGFA to cause IVNV,34,36 and these articles also used
the mouse model of OIR that exposes pups to constant and
higher oxygen levels than currently used in the manage-
ment of ROP.37
In the current study, we generated shRNAs to VEGFA
and used a lentiviral miRNA-based system to target Müller
cells, where the VEGFA message was localized in the
50/10 OIR model. We tested the hypothesis that knocking
down VEGFA to physiological levels in Müller cells
would inhibit IVNV without adversely affecting physio-
logical retinal vascular development.The American Journal of Pathology - ajp.amjpathol.orgMaterials and Methods
Rat Model of the 50/10 OIR Model
All animal studies were performed in compliance with the
University of Utah (Salt Lake City) Guide for the Care and
Use of Laboratory Animals and the Association for
Research in Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmic and Vision Research. The rat
50/10 OIR model has been previously described.38 Entire
litters of newborn Sprague-Dawley rat pups (Charles River,
Wilmington, MA) and dams were placed into an oxygen
environment (Oxycycler; Biospherix, Lacona, NY) that
cycled the oxygen concentration between 50% and 10%
every 24 hours for 14 days. At postnatal day 14 (p14), litters
were placed into room air for an additional 4 days. Pup
number was maintained at 12 to 14 pups per litter. At least
two litters were used for each condition. Protein, in situ
hybridization, or immunohistochemistry (IHC) was per-
formed in one eye, and ﬂat mount analysis was performed in
the fellow similarly treated eye.
In Situ Hybridization of VEGFA Splice Variants
Serial sections (10 mm thick) from fresh frozen p14 50/10
OIR uninjected eyes were processed for in situ hybridization
to detect the message of VEGF120, VEGF164, and VEGF188
splice variants using the ﬂuorescence in situ hybridization
(FISH) kit (Invitrogen, Carlsbad, CA), per manufacturer’s
instructions. In comparison, serial retinal sections from
a room aireraised pup at developmental day p14 were
processed at the same time. Labeling of nuclei was per-
formed using Hoechst 33342 (Invitrogen, Carlsbad, CA).
Construction of VEGFA shRNA Lentivectors
Studies have shown that double-stranded RNAs can bind the
surface of cells and activate toll-like receptor 3.39 We chose
shRNAs packaged within a virus, rather than as siRNA, so
the RNA will not have access to the surface toll-like receptor
3. We embedded shRNAs into the endogenous precursor
miR-30 context, so that the miRNA-based shRNA will be
involved in the endogenous gene-silencing machinery that is
transcribed predominantly by polymerase II promoters.
Target sequences for rat VEGFA (NM_031836) were
selected from ﬁve online prediction algorithms based on
regions predicted to work in more than two of the algo-
rithms. Sequences were blasted to ensure no off-target
effects. For VEGFA, the target sequences were selected in
the region of bases between 100 and 419 so that no alter-
native splice sites were targeted and to ensure that all splice
variants would be silenced. A sequence-targeting non-
mammalian gene, luciferase (M15077), was developed as
a control. The lentiviral transfer vector with a CD44
promoter and the red ﬂuorescence protein (RFP) or green
ﬂuorescence protein (GFP) (pFmCD44.1GW), along with965
Wang et alviral packaging constructs (VSV-G, pMDLg/pRRE, and
pRSV-REV), were shown to target Müller cells in rats
in vivo.40 shRNAs were designed against rat VEGFA
(VEGFA-shRNA) or luciferase (luciferase-shRNA) and
cloned into lentiviral transfer vectors (pFmCD44.1GW).
Viral titers were determined using real-time quantitative
PCR for viral particles, with ﬁnal viral working stocks of 1
 109 viral particles/mL. The sequences of VEGFA-shRNA
and luciferase-shRNA were 50-TGCTGTTGACAGTGAG-
CGCCCAAAGAAAGATAGAACAAAGTAGTGAAGCC-
ACAGATGTACTTTGTTCTATCTTTCTTTGGTTGCCTA-
CTGCCTCGGA-30 and 50-TGCTGTTGACAGTGAGCGC-
GCTGAGTACTTCGAAATGTCTAGTGAAGCCACAGA-
TGTAGACATTTCGAAGTACTCAGCGTGCCTACTGC-
CTCGGA-30, respectively.
Generation of VEGF120 and VEGF164 HEK Reporter Cell
Lines
Two HEK reporter cell lines were generated by cloning rat
VEGF120 and VEGF164 cDNA sequences into a pTK642
lentiviral transfer vector to test the efﬁcacy of shRNAs to
inhibit all splice variants of VEGFA. pTK642 contains
a cytomegalovirus promoter, followed by an interferon
response element and blasticidin/GFP. The GFP reporter
was used to assess transfection efﬁciency, whereas the
blasticidin permitted selection of cells that expressed rat
VEGF120 and rat VEGF164. Both HEK VEGFA reporter cell
lines were transfected with plasmid DNA pFmCD44.1GW
containing VEGFA-shRNA expressed with RFP or an
empty vector without shRNA as control. The knockdown
efﬁciency of VEGFA-shRNA was determined by reading
GFP ﬂuorescence 48 hours after transfection of HEK VEGF
reporter cell lines with ﬂow cytometry. Red cells were
gated, and the mean ﬂuorescence intensity of GFP was
measured. Silencing was calculated as the difference in GFP
mean ﬂuorescence intensity between cells transfected with
the vector containing the VEGFA-shRNA and cells con-
taining the control vector. Silencing was expressed as
a percentage of control vector transfected cells.
Cell Culture and Transduction with pFmCD44-shRNA
Lentivectors
rMC-1 cells, a rat Müller cell line (kindly provided by Dr.
Vijay Sarthy, Northwestern University, Evanston, IL), were
maintained in Dulbecco’s modiﬁed Eagle’s medium/high
glucose (Gibco/Life Technologies, Grand Island, NY),
supplemented with 10% fetal bovine serum/1% penicillin-
streptomycin and grown to 80% conﬂuence in 6-well plates
(Corning, Inc., Corning, NY). Human primary retinal
microvascular endothelial cells at passage 3 (hRMVECs;
Cell Systems, Kirkland, WA) were maintained in basal
endothelial growth medium (Lonza, Hopkinton, MA), sup-
plemented with 5% fetal bovine serum/1% penicillin-
streptomycin and grown to 80% conﬂuence in 6-well966plates (Corning, Inc., Tewksbury, MA). Cells were infected
in triplicate with VEGFA-shRNA or luciferase-shRNA lenti-
vector-containing media (5.0  106 viral particles/mL) or left
uninfected. After 24 hours, media were replaced, and cells
were then incubated for another 18 hours at 37C at 1% O2
(Biospherix). GFP expression was imaged using an inverted
ﬂuorescence microscope (Olympus IX81; Olympus, Tokyo,
Japan) at 20 magniﬁcation with a ﬂuorescein isothiocyanate
ﬁlter. rMC-1 cells were collected for RNA extraction and
analysis with real-time PCR. Media were harvested for
VEGFA enzyme-linked immunosorbent assay (ELISA). All
samples were frozen at 80C until analysis.
Co-Culture of rMC-1s and hRMVECs
hRMVECs were grown on inserts (Transwell; Corning,
Inc.) with 1-mm-diameter pores that were too small to allow
cell migration but still allowed hRMVEC and rMC-1 cells
grown on the underside of the inserts to make contact. In
some experiments, rMC-1 cells were infected with lenti-
vector VEGFA-shRNA or luciferase-shRNA, as previously
described. At 48 hours after contact and virus infection,
hRMVECs were collected from the tops of the inserts and
processed for VEGFR2 phosphorylation.
Subretinal Injections
At the beginning of the 50% oxygen cycle of the 50/10 OIR
model on p8, pups were anesthetized by i.p. injection (IP) of
20 mg/kg ketamine and 6 mg/kg xylazine. By using a 33-
gauge needle attached to a Hamilton syringe, 1 mL (1  109
viral particles/mL) of lentivectors containing VEGFA-
shRNA or luciferase-shRNA was delivered into the sub-
retinal space. Sterile PBS (1 mL) was used as an additional
control. Successful injections produced a retinal detachment,
which was transient, and retinas reattached within 24 hours
without lens injury or injury to the choroid. Both eyes of each
pup were injected with the same lentivector preparation or
with PBS. Each litter typically had an equal distribution of
lentivector- and PBS-injected pups. After the injection, 0.5%
erythromycin was topically applied to each eye, and pups
were allowed to recover on a warming pad before being
returned to the oxygen environment (Oxycycler). Litters were
typically out of the oxygen cycler for 3 hours. At postnatal day
18 (p18), a time point that we have found maximum IVNV in
this model,41 and to provide sufﬁcient time for lentivirus
transduction and VEGFA knockdown, pups were euthanized
by IP of ketamine (60 mg/kg) and xylazine (18 mg/kg), fol-
lowed by IP of pentobarbital (80 mg/kg). One eye was pro-
cessed for retinal ﬂat mounts, and the fellow eye was processed
with the same treatment for protein or RNA analysis.
In Vivo Retinal Imaging
Pups were anesthetized for in vivo imaging of the retinas
with Micron III retinal imaging microscope (Phoenix
Research Laboratories, Inc., Pleasanton, CA) using a GFPajp.amjpathol.org - The American Journal of Pathology
Müller CelleDerived VEGFA Regulates IVNVﬁlter during the 50% oxygen cycle and returned to the
oxygen chamber for recovery within 3 hours. For eutha-
nasia, pups received IP of pentobarbital (80 mg/kg) after
deep anesthesia.
Retinal Flat Mount Preparation, Imaging, and Analysis
Lectin-stained retinal ﬂat mounts were prepared using 5 mg/mL
Alexa Fluor 568econjugated Griffonia simplicifolia (Bandeir-
aea) isolectin B4 (Molecular Probes, Eugene, OR), as previ-
ously described,10 imaged using an inverted ﬂuorescence
microscope (Olympus). Flat mounts were generated using the
scan-slide stitching function of Metamorph imaging software
version 7.0 (Molecular Devices, Inc., Sunnyvale, CA). Mea-
surementsweremadeby twomasked reviewers (Y.J. andM.M.)
using ImageJ software version 1.46 (NIH, Bethesda, MD). The
avascular retinal area (AVA) and IVNV area were calculated as
a percentage of total retinal area for each ﬂat mount.
Retinal Section Preparation and Staining and Retinal
Thickness Measurement
Eyes were ﬁxed in 4% paraformaldehyde containing 10
mmol/L sodium orthovanadate for 10minutes, and retinas were
removed and placed into 4% paraformaldehyde for another 15
minutes, followed by incubation in 30% sucrose/PBS over-
night. Each retinawas immersed in optimal cutting temperature
compound (Tissue Tek; EMS, Hatﬁeld, PA). Eyes cut into
cryosections (10 mm thick) were processed, as described
previously,10 and incubated overnight at 4C with primary
antibody, rabbit anti-phosphorylated VEGFR2 (p-VEGFR2 at
Y951; Santa Cruz Biotechnology, Santa Cruz, CA), and mouse
isolectin B4; then, they were washed and incubated for 1 hour
with a 1:500dilution ofAlexa 594econjugatedgoat anti-mouse
secondary antibody (Invitrogen) for isolectin B4 or Alexa
488econjugated goat anti-rabbit secondary antibody (Invi-
trogen) for p-VEGFR2. Some sections stained with only
secondary antibody were controls. Cryosections stained with
DAPI were used to measure retinal thickness. Images were
captured using confocal microscopy (Olympus IX81). Expo-
sure times for images were the same. Integrated density per
image area of p-VEGFR2 and thickness of overall retina and
different retinal layers were measured using ImageJ software.
VEGFA ELISA
Protein samples (50 mg) were used in the Quantikine Rat
VEGFA ELISA kit (RRV00; R&D Systems, Minneapolis,
MN) to measure total retinal VEGFA concentration between
treatment groups, per manufacturer’s instructions. All
samples were run in duplicate.
Protein Extraction and Western Blot Analysis
The hRMVECs were lysed in modiﬁed radio-
immunoprecipitation assay buffer (20 mmol/L Tris base,The American Journal of Pathology - ajp.amjpathol.org120 mmol/L NaCl, 1% Triton X-100, 0.5% sodium deoxy-
cholate, 0.1% SDS, and 10% glycerol) with 1:100 protease
inhibitors (Roche Diagnostics, Indianapolis, IN) and 2
mmol/L orthovanadate, and were homogenized and centri-
fuged at 16,000  g for 10 minutes at 4C. Total protein
concentration (g/mL) in the supernatant ﬂuid was quantiﬁed
by BCA protein assay (Pierce, Rockford, IL). Total protein
(30 mg) for each sample was used for Western blot analyses,
as described previously.10 Membranes were incubated
overnight at 4C with primary antibodies: p-VEGFR2,
VEGFR2 (1:500; Santa Cruz Biotechnology), cleaved cas-
pase 3, and total caspase 3 (1:1000; Cell Signaling Tech-
nology Inc., Danvers, MA). Blots were visualized, and the
relative densities of bands were calculated as previously
described.10 The relative activities of STAT3 and VEGFR2
were calculated as phosphorylated/total protein and
expressed as fold difference. Caspase 3 activity was analyzed
by Western blot analysis and quantiﬁed as the density of the
bands for the cleaved form/density of total caspase bands.
RNA Isolation and Real-Time PCR Analysis
Samples were removed from RNAlater, and total RNA was
extracted with the RNeasy Mini kit (Qiagen, Valencia, CA).
RNA was quantiﬁed using the NanoDrop spectrophotometer
(Thermo Scientiﬁc, Wilmington, DE). cDNA was generated
using a High Capacity cDNA Archive Kit (Applied Bio-
systems, Foster City, CA). Real-time PCR was performed on
a Mastercycler ep Realplex (Eppendorf, Westbury, NY) with
the use of TaqMan probes (Applied Biosystems). Expression
levels for VEGFA were normalized to the mean value of
internal control, glyceraldehyde-3-phosphate dehydrogenase.
Statistical Analysis
Signiﬁcant differences between treatment groups were
determined by one-way analysis of variance with the Bon-
ferroni multiple-comparison post hoc test. A minimum
value of P < 0.05 was considered statistically signiﬁcant.
Results
VEGFA Splice Variants Localize to Layers Corresponding
to CRALBP-Labeled Müller Cells in the 50/10 OIR Model
We previously reported that VEGFA splice variant expres-
sion increased in the retinas of rat pups exposed to the 50/10
OIR model at time points including p14 and p18, compared
with retinas from age-matched pups raised in room air. 30,41
We, therefore, localized VEGFA mRNA splice variants,
VEGF120, VEGF164, and VEGF188, within the retinas of rat
pups raised in the 50/10 OIR model and in room air at p14.
The mRNA signals in both room aireraised pups and the
50/10 OIR model, determined by FISH, were mainly in the
inner nuclear layer, corresponding to CRALBP-labeled
Müller cells, and retinal pigment epithelium in both the967
Figure 1 mRNA of VEGFA splice variants is localized in the inner nuclear
layer (INL) corresponding to Müller cells in the rat 50/10 OIR model. FISH of
VEGFA splice variants (VEGF120, VEGF188, and VEGF164) in retinal cryosections
at p14 shows the VEGFA splice variant message in regions where CRALBP-
labeled Müller cells were present (A) in the rat 50/10 OIR model (BeD)
and in a room aireraised pup at p14 (RA; EeG). The expression of VEGFA is
also present in the external limiting layer, retinal pigment epithelium (RPE),
and photoreceptor regions. GCL, ganglion cell layer; ONL, outer nuclear layer.
Wang et al50/10 OIR model and room air (Figure 1). These results
support the hypothesis that Müller celleproduced VEGFA
may be involved in VEGFA-mediated pathological angio-
genesis in the 50/10 OIR model.
Generation of Lentivectors for VEGFA-shRNA Delivery
to Müller Cells
To investigate whether Müller cellederived VEGFA
contributed to IVNV, we generated lentivectors from
pFmCD44.1 GW, which contains a CD44 promoter that
targetsMüller cells,40 and used this to drive anmiR-30ebased
shRNA cassette and RFP (Figure 2A) or GFP (Figure 3A) to
deliver VEGFA shRNAs toMüller cells in vitro or in vivo. To
ensure knockdown efﬁciency, two shRNAs targeting rat
VEGFA coding sequences were designed, and an empty len-
tivector was used as a control. To test if designed shRNAs
reduced VEGFA expression, HEK reporter cell lines were
generated that expressed GFP-tagged rat VEGF120 or
VEGF164 (Figure 2B). Lentivector plasmid DNA containing
VEGFA-shRNA with RFP expression was transfected into
HEK reporter cell lines. Fluorescence-activated cell sorter
analysis ofGFPﬂuorescence inRFP-positive cellswas used as
a readout for the expression level of VEGF120 and VEGF164,
two splice variants of VEGFA (Figure 2C). As shown in
Figure 2D, VEGFA-shRNA2 showed better knockdown
efﬁciency than VEGFA-shRNA1, with 35% reduction in
VEGF120 expression and approximately 50% reduction in
VEGF164 expression. Therefore, VEGFA-shRNA2 was used
for in vivo experiments.968To determine whether the lentivector speciﬁcally targeted
Müller cells, a rat Müller cell line, rMC-1s, and, as a com-
parison, hRMVECs, were infected with GFP-expressed lenti-
virus carrying VEGFA-shRNA2 or luciferase-shRNA control
virus (Figure 3A). Speciﬁcity to Müller cells was determined
byGFPexpression, as shown inFigure3B,where rMC-1swere
GFP positive, and no hRMVECs were GFP positive. At 48
hours after viral transduction, VEGFA mRNA was signiﬁ-
cantly reduced in VEGFA-shRNAetransduced rMC-1s
(Figure 3C), and VEGFA protein was signiﬁcantly decreased
in the culture media of VEGFA-shRNAetransduced rMC-1s
compared with uninfected cells or cells transduced with lenti-
vector with luciferase-shRNA (Figure 3D). These results
suggest that lentivectors transporting shRNAs to VEGFA
yielded a satisfactory reduction of VEGFA expression at both
mRNA and protein levels.
To further test if knockdownofVEGFA in rMC-1s is able to
reduce VEGFA signaling in retinal endothelial cells, a co-
culture model of rMC-1s and hRMVECs was used. As shown
in Figure 3E, compared with solo cultured hRMVECs,
p-VEGFR2 was increased in hRMVECs either grown in
contact with rMC-1 for 24 hours or treated with human
VEGFA for 30 minutes, suggesting the co-culture model was
feasible to test our hypotheses. To further examine the effect of
Müller cellederived VEGFA on the activation of hRMVEC
VEGFA signaling, activation of VEGFR2 was determined in
hRMVECs grown in contactwith rMC-1 cells transducedwith
lentivector VEGFA-shRNA or control luciferase-shRNA.
Similar to the results shown in Figure 3C, VEGFA mRNA
was signiﬁcantly reduced in rMC-1s transduced with lenti-
vector VEGFA-shRNA, and p-VEGFR2 was also decreased
in hRMVECs when cells were in contact with lentivector
VEGFA-shRNAetransduced rMC-1s, comparedwith control
luciferase-shRNA (Figure 3F). These ﬁndings support the
hypothesis that modulating VEGFA expression in rMC-1s
changedVEGF-mediated angiogenic signaling in hRMVECs.
Knockdown of VEGFA in Müller Cells Reduces IVNV
without Affecting Retinal Physiological Vascularization
In the 50/10 OIR model, we found VEGFA was increased as
early as p8 and was up-regulated at several time points
through p18,30 when IVNV is at a maximal level.37 To
investigate whether knockdown of VEGFA in Müller cells
reduced IVNV in the 50/10 OIR model, lentivectors
carrying VEGFA-shRNA or control luciferase-shRNA were
delivered to rat pups via subretinal injections at p8, a time
point that allowed sufﬁcient time for viral transduction. We
(data not shown) and Greenberg et al40 previously found
that intravitreal injections did not yield Müller cell trans-
duction. Only pups weighing within 2 g of the average
weight of the litters received injections and were included in
the following experiments; thus, body weights at p8 were
similar between the virus injection and control groups. In
addition, pup number was maintained between 12 and 14 in
all litters to ensure consistency in the 50/10 OIR model.28ajp.amjpathol.org - The American Journal of Pathology
Figure 2 Generation of lentivector-delivered shRNA
for speciﬁc knockdown of VEGFA in Müller cells. A:
Diagram of the pFmCD44.1GW lentivector containing the
glia-speciﬁc CD44 promoter driving an miR-30ebased
shRNA cassette and an RFP marker. B: HEK293 reporter
cell line expressed GFP-tagged rat VEGF120 or VEGF164. C:
HEK reporter cell lines to VEGF120 and VEGF164 were
transfected with RFP-expressed lentivector VEGFA-shRNA
plasmids, and GFP ﬂuorescence (infectivity) was
measured by ﬂow cytometry. D: Quantiﬁcation of
percentage silencing of VEGF120 and VEGF164 by VEGFA-
shRNAs from ﬂuorescence-activated cell sorter analysis
(nZ 3). Results are means  SEM.
Müller CelleDerived VEGFA Regulates IVNVTo determine the extent of viral transduction in the retina,
retinal images were captured in vivo using the Micron III
retinal imaging microscope. As shown in Figure 4A, the
retina had GFP ﬂuorescence by p18. Rat pups were sacriﬁced
at p18, and one eye was analyzed for IVNV and avascular
retina, and the other for protein or IHC. By IHC, we found
GFP colocalized with CRALBP-labeled Müller cells, as
shown in an experiment using control lentivirus with the
CD44 promoter to drive GFP (Figure 4B), providing addi-
tional support that the lentivirus was transduced in Müller
cells. To determine the silencing effect of the lentivector-
delivered shRNA in vivo, total retinal VEGFA protein wasThe American Journal of Pathology - ajp.amjpathol.orgmeasured by ELISA. Consistent with our previous ﬁndings,
VEGFA protein was increased in retinas from pups raised in
the 50/10 OIR model at p18 compared with room aireraised
pups (Figure 4C). Compared with pups receiving subretinal
injections of PBS or luciferase-shRNA controls, retinal
VEGFA was signiﬁcantly reduced in pups that received
VEGFA-shRNA virus injections (Figure 4C). However,
compared with room aireraised pups of the same postnatal
day ages, there was no signiﬁcant difference in VEGFA
levels in retinas from p18 pups in the 50/10 OIR model and
treated with VEGFA-shRNA virus, suggesting that lenti-
vector VEGFA-shRNA reduced VEGFA to physiologicalFigure 3 In vitro analysis of lentivector-
delivered shRNA transduction and VEGFA knockdown
in rMC-1 cells, and VEGFA signaling in a co-culture
model of rMC-1s and hRMVECs. A: Diagram of the
pFmCD44.1GW lentivector plasmid containing the
glia-speciﬁc CD44 promoter driving anmiR-30ebased
shRNA cassette andaGFPmarker.B: GFP expression in
rMC-1s andhRMVECs. Real-timePCR of VEGFAmRNA in
rMC-1s (C) and ELISA of VEGFA protein in culture
media of rMC-1s transduced with lentivirus (D). E and
F: Knockdown of VEGFA in rMC-1s by lentivector-
VEGFA-shRNA reduces co-cultureeinduced p-VEGFR2
in hRMVECs. Representative gels of p-VEGFR2 in
hRMVECs grown in contact with lentivector VEGFA-
shRNA or luciferase-shRNAetransduced rMC-1s (E)
(solo cultured, treated with VEGFA, and grown in
contact with rMC-1s) and in hRMVECs grown in
contact with lentivector VEGFA-shRNAe or luciferase-
shRNAetransduced rMC-1s (F). *P < 0.05, ***P <
0.001 versus uninfected; yP < 0.05, yyyP < 0.001
versus luciferase-shRNA. Data shown in C and D
are representative of six independent samples.
Results are means  SEM. GAPDH, glyceraldehyde-
3-phosphate dehydrogenase.
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Wang et allevels required for normal retinal vascular development. To
determine the VEGFA knockdown, we colabeled retinal
cryosections with VEGFA and glutamine synthetase from
eyes injected with lentivector VEGFA-shRNA or luciferase-Figure 5 Lentivector-VEGFA-shRNA reduces IVNV without interfering
with physiological retinal vascular development in the rat 50/10 OIR model.
A: Images of retinal ﬂat mounts at p18 after subretinal injections in each
group (PBS, control luciferase-shRNA, and VEGA-shRNA). B and C: Quanti-
ﬁcation of IVNV (**P < 0.01 versus PBS; yyyP < 0.001 versus luciferase-
shRNA; B) and AVA (P Z 0.85, luciferase-shRNA versus PBS; P Z 0.15,
VEGFA-shRNA versus PBS; C) in each group. Data shown in B and C are
representative of 12 independent samples. Results are means  SEM. In
panel A, asterisks indicate AVA; arrows, area with IVNV.
970shRNA. Immunoreactivity of VEGFA was reduced in
sections from VEGFA-shRNA injection compared with
luciferase-shRNA or uninjected eyes from the 50/10 OIR
model at p18 (Figure 4D).
We then determined the effect of lentivector VEGFA-
shRNA subretinal injections on IVNV and percentage
AVA. For AVA, there was no difference in control or PBS-
treated eyes with VEGFA-shRNAetreated eyes (Figure 5,
A and C). However, there was a signiﬁcant reduction in
percentage IVNV in lentivector VEGFA-shRNAetreated
eyes compared with the other groups (Figure 5, A and B).
These ﬁndings provide evidence that Müller cellederived
VEGFA contributed to IVNV, and suggest that knockdown
of up-regulated VEGFA in Müller cells reduced patholog-
ical IVNV without interfering with physiological retinal
vascular development or affecting retinal apoptosis in the
50/10 OIR model at p18.
Reduced pup growth rate, or extrauterine growth restric-
tion, is an associated risk factor for severe ROP in human
infants.42 We found no signiﬁcant differences in mean pup
weights measured at p18 in all groups, as shown in Figure 6A.Figure 4 In vivo analysis of lentivector-delivered shRNA transduction in
retina of pups raised in the rat 50/10 OIR model at p18 after subretinal
injection at p8. A: Images by Micron III retinal imaging microscope showed
GFP expression in retina of pups after lentivirus injection compared with the
PBS-injected pup. B: GFP expression is localized with CRALBP-labeled Müller
cells in retinal cryosections at p18 taken from pup eye injected at p8 with
lentivirus containing CD44 promoter driving GFP expression. C: ELISA of
retinal VEGFA protein at p18. ***P< 0.001 versus uninjected room air raised
(RA), yyP < 0.01 versus PBS, and zP < 0.05 versus luciferase-shRNA. Results
are means  SEM (n Z 6 to 8). D: IHC of VEGFA protein in glutamine-
synthetaseelabeled Müller cells at p18, showing reduced immunoreac-
tivity of VEGFA in VEGFA-shRNAetreated eyes compared with uninjected or
control injected eyes from the 50/10 OIR model at p18. GCL, ganglion cell
layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear
layer; OPL, outer plexiform layer; RPE, retinal pigment epithelium.
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Figure 6 Injection of lentivirus does not cause systemic effects or retinal
morphological changes in the rat 50/10 OIR model. A: Weight gain of pups
from p8 to p18. B: Rectal temperature at p18. C and D: Retinal cross sections
stained with DAPI at p18 (C) show no difference in thickness of overall retina
and inner nuclear layer (D). E: Retinal-activated caspase 3 at p18. P> 0.05 for
VEGFA-shRNA versus either PBS or luciferase-shRNA. Results aremeans SEM
(nZ 5 to 15). GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner
plexiform layer; ONL, outer nuclear layer; OPL, outer plexiform layer.
Figure 7 Knockdown of VEGFA in Müller cells by lentivector-VEGFA-
shRNA reduces VEGFA signaling in vivo. A: p-VEGFR2 labeling (green) in
a cross section through isolectin-stained (red) IVNV or DAPI (blue). B:
Quantiﬁcation of p-VEGFR2 density in IVNV. *P < 0.05 for VEGFA-shRNA
versus luciferase-shRNA (n Z 3). Results are means  SEM.
Müller CelleDerived VEGFA Regulates IVNVRectal temperature measured at p18 as an indicator of viral-
induced systemic inﬂammation was also not different
between the PBS, control, or VEGFA-shRNA lentiviruse
injected groups (Figure 6B). In addition, lentivirus injection
did not cause changes in retinalmorphological characteristics,
retinal thickness, or thickness of the inner nuclear (Figure 6, C
and D), outer nuclear, inner plexiform, or outer plexiform
layers (quantiﬁcation is not shown). To determine whether
lentivirus injection caused increased apoptosis, we measured
retinal caspase 3 activity and found that there was no signif-
icant difference in retinas between PBS-treated eyes and
either VEGFA-shRNAe or luciferase-shRNAetreated eyes
(Figure 6E).
Knockdown of VEGFA in Müller Cells Reduces VEGFA
Signaling in Retinal Vascular Endothelial Cells
Based on the previously described results, we hypothesized
that down-regulation of VEGFA in Müller cells reduced
VEGF receptor signaling in retinal vascular endothelial
cells. To test this hypothesis, we measured p-VEGFR2 in
retinal cryosections by IHC (Figure 7). We found that,
compared with luciferase-shRNA, the density of p-VEGFR2
(Figure 7, A and B) labeling normalized to the IVNV area,
determined by lectin-positive staining, was qualitatively
decreased in sections from pups that received lentivector
VEGFA-shRNA in the 50/10 OIR model.The American Journal of Pathology - ajp.amjpathol.orgDiscussion
Elevated VEGFA has been found in the vitreous of infants
with ROP.15 Evidence from animal studies indicates that
hypoxia induces VEGFA expression and causes the patho-
logical phases seen in ROP.30,37,43 Several types of retinal
cells produce VEGFA either in pathological or physiolog-
ical conditions, making broad and total inhibition of
VEGFA signaling in the retina a concern, particularly in
preterm infants in whom vasculature, neurons, and the
neurovascular connections are developing.37,43 Therefore,
targeting speciﬁc cells that overproduce VEGFA to knock
down excessive expression without inhibiting physiological
expression may reduce pathological features without inter-
fering with development and maturation. By using the
mouse model of OIR, investigators concluded that Müller
cell34 or astrocyte-derived VEGFA36 was important in
pathological angiogenesis. To address current-day ROP in
countries that have resources to avoid high oxygen at birth,
we used a rat model of variable OIR, the 50/10 OIR model,
to assess overexpressed VEGFA that developed after birth
from stresses relevant to those experienced by current-day
human preterm infants.30,43
We previously reported that repeated ﬂuctuations in
oxygen up-regulated VEGFA expression in the retina at
several time points in the rat 50/10 OIR model, compared
with room aireraised pups, that corresponded with persistent971
Wang et alavascular retina and IVNV, which are features similar to
those in human severe ROP.30,44 By using the same model,
we also found that inhibiting rat VEGFA with a neutralizing
antibody signiﬁcantly reduced IVNV area by approximately
3.5-fold, but caused adverse effects, including reduced pup
growth between the time of intravitreal injection at postnatal
day 12 and the time of sacriﬁce at p18.27 Therefore, to better
target cells that overexpress VEGFA, we localized VEGFA
mRNA in retinal sections using ﬂuorescence in situ hybrid-
ization (FISH). Fourteen days after pups were exposed to
repeated ﬂuctuations in oxygen, mRNA signals of retinal
VEGFA splice variants were detected in the inner nuclear
layer and colocalized with CRALBP. Therefore, we postu-
lated that Müller cellederived VEGFA might mediate
pathological angiogenesis in the form of IVNV. To knock
down Müller cellederived VEGFA, shRNAs to VEGFA
were designed and inserted into a lentiviral miR-30ebased
system driven by a CD44 promoter (as shown in Figures 2A
and 3A), which was shown to exclusively target Müller cells
in vivo in the rat.40 Usually, shRNA expression is under the
control of polymerase III promoters, such as the U6
promoter, which drives shRNA expression in all cells. To
express shRNA only in Müller cells driven by the CD44
promoter that is regulated by polymerase II, we embedded
the shRNAs within an miR-30 context. The expression of the
miR-30ebased shRNAs is transcribed by the polymerase
IIeregulated CD44 promoter. The use of a polymerase II
promoter to drive miR-30ebased shRNAs has been shown to
yield more efﬁcient knockdown of the target gene than
standard shRNA constructs.45,46
We found that the lentivector-driven miR-30eVEGFAe
shRNA was speciﬁcally expressed in Müller cells. By using
several cell models and molecular approaches, we determined
an optimal lentivector pFmCD44-driven VEGFA-shRNA that
efﬁciently and speciﬁcally reduced Müller cellederived
VEGFA in vitro, even though the knockdown efﬁciency was
not high. That the CD44 promoter may have lower activity
in vitro than in vivo40,46 may explain the relatively low
silencing of VEGFA by lentivector-VEGFA-shRNA. How-
ever, the VSV-G-CD44 promoter conﬁguration was shown to
yield high transduction efﬁciency and speciﬁcity for Müller
cells in vivo.40
We then determined if the lentivectors used would speciﬁ-
cally target Müller cells in vivo and knock down VEGFA
expression. We found p18 to be the time for development of
maximal IVNV in the rat 50/10OIRmodel.41 For the lentivirus
to transduce Müller cells, approximately a week is needed.
Injections administered too early might adversely affect
developingMüller cells. Based on these concerns and previous
experiments, the time point, p8, was chosen to administer
subretinal injections. Our previous study showed that retinal
VEGF expression increased in the 50/10OIRmodel as early as
postnatal day 8 and became maximal at p14.41 In this study,
pups received lentivirus at p8, which we reasoned would
provide 1 week for effective and safe shRNA transduction and
knockdown of up-regulated VEGFA. Ten days after subretinal972injections at p18, live imaging using the Micron III retinal
imaging microscope showed GFP expression in retinas from
pups injected with either lentivector luciferaseeshRNA or
VEGFA-shRNA, and this GFP expression was colocalized
with CRALBP-labeled Müller cells in retinal cryosections.
ELISA analysis showed that pups injected with VEGFA-
shRNA had decreased VEGFA protein in retina compared
with uninjected pups and pups injected with luciferase-
shRNAedelivered virus, but therewas nodifference compared
with pups raised in room air, suggesting lentivector-VEGFA-
shRNA reduced 50/10 OIR-induced VEGFA from patholog-
ical levels to the levels required to maintain physiological
retinal development. We then showed that transduction of
Müller cells with VEGFA-shRNA in retinas of pups in the
50/10 OIR model caused almost complete inhibition of IVNV
and some, albeit insigniﬁcant, inhibition of AVA compared
with control (P Z 0.15). In addition, the vascular morpho-
logical characteristics of VEGFA-shRNAetreated retinas
appeared more normal than those of control or PBS-injected
eyes, suggesting that reducing VEGF to physiological levels
permits physiological-appearing retinal vascularization. In
previous studies, comparing ﬂat mounts from pups adminis-
tered intravitreal anti-VEGF antibody injections with nonim-
mune IgG control injections,27 IVNV was reduced, but
vascular morphological features still lacked physiological
morphological features compared with eyes that had been
treated with lentivector-VEGFA-shRNA (Supplemental
Figure S1). Although there can be associated damage with
subretinal injections and subsequent retinal detachment,
we and others47 found that the bleb, or limited retinal
detachment, associated with a successful subretinal injection
was temporary and resolved within 24 hours, as determined
using Micron III retinal imaging microscope. In addition,
therewas no increase in retinal apoptosis or changes in retinal
morphological features with lentivector injections. Ocular
injections of lentivirus also did not cause adverse effects on
pup weight gain or systemic inﬂammation, as determined by
rectal temperature.
Therefore, these results support the hypothesis that tar-
geted partial silencing in cells that overexpress VEGFA (ie,
Müller cells) can effectively inhibit pathological IVNV
without interfering with physiological retinal vascular
development or reducing weight gain during development
using a model of OIR that is relevant to current-day ROP.
Müller cells provide nutrition for retinal neurons, and abla-
tion of Müller cells causes retinal vascular pathological
features in a transgenic mouse model,48 suggesting interac-
tions may exist between Müller cells and retinal vascular
endothelial cells. To identify whether knockdown of Müller
cellederived VEGFA, using these lentivector-delivered
shRNAs, caused decreased VEGFA signaling in hRMVECs,
we measured p-VEGFR2 in IVNV labeled with isolectin
in retinal cryosections and found signiﬁcantly reduced
p-VEGFR2 staining per area of IVNV in pups injected with
lentivirus-delivered VEGFA-shRNA. To further test our
hypothesis, a co-culture of rMC-1s and hRMVECs wasajp.amjpathol.org - The American Journal of Pathology
Müller CelleDerived VEGFA Regulates IVNVperformed. We found no signiﬁcant difference in the acti-
vation of VEGFR2 in hRMVECs after growth with rMC-1s
compared with that with human VEGFA stimulation, sup-
porting the use of the rat/human co-culture to address this
question. We then determined that knockdown of VEGFA in
rMC-1s by lentiviral-delivered VEGFA-shRNA reduced
VEGFR2 signaling in hRMVECs in co-culture. The results
together indicated that knockdown of Müller cellederived
VEGFA effectively inhibited VEGFA-regulated angiogen-
esis in retinal vascular endothelial cells.
In summary, we localized VEGFA overexpression in
Müller cells and generated a lentiviral-delivered miR-
30eembedded shRNA that targeted Müller cells and efﬁ-
ciently reduced VEGFA from pathological levels to levels
required for physiological retinal vascular development using
a model relevant to ROP today, the 50/10 OIR model.
Although we do not propose either subretinal injections or
gene therapy to treat human infants with ROP, this study
provides a novel concept to examine mechanisms involved in
pathological IVNV and may be useful to determine phar-
macological targets to safely reduce pathological features of
ROP without interfering with the beneﬁcial effect of major
growth factors. In future studies, we will analyze the effects
of targeting Müller cellederived VEGF on the regression of
IVNV and physiological retinal vascularization at later time
points in the model.
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